Share on Pinterest Getty Images/Dragoljub Bankovic The FreeStyle Libre is a continuous glucose monitoring (CGM) system that doesn’t require a blood sample from a finger stick. It’s ...

Abbott's REFLECT real-world retrospective studies indicate that FreeStyle Libre continuous glucose monitoring (CGM) technology use is linked to a significant decrease in hospitalisation risk for ...

The US Food and Drug Administration (FDA) has cleared the Abbott Libre 2 and 3 continuous glucose monitoring (CGM) sensors for use during most imaging procedures, including MRI under certain ...

Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk ...

Abbott has entered a global partnership focusing on the integration of its advanced FreeStyle Libre continuous glucose monitoring (CGM) technology with the Medtronic automated insulin delivery ...

Abbott (NYSE: ABT), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $223.67 billion, has released findings from its REFLECT studies indicating that ...

FreeStyle Libre is a continuous glucose monitoring (CGM) system that allows a person to check their blood sugar in real time without having to prick their finger. The system has two components ...

May 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology ...